Repatha vs Crestor
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| CA Repatha | CA Crestor | |
|---|---|---|
| Generic name | evolocumab | rosuvastatin |
| Drug class | PCSK9 Inhibitor (Biologic) | Statin |
| Treats | High cholesterol, cardiovascular disease | High cholesterol, cardiovascular prevention |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Amgen | AstraZeneca |
| Year approved | 2015 | 2003 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $32M | $7M |
| Common side effects | Injection site reactions, Allergic reactions, Back pain, Fatigue | Muscle pain, Headache, Liver problems, Weakness |
Frequently asked questions
Is Repatha or Crestor better?
Neither is universally "better." Repatha (evolocumab) and Crestor (rosuvastatin) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Repatha and Crestor?
Repatha is a PCSK9 Inhibitor (Biologic) made by Amgen, while Crestor is a Statin made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Repatha has the larger estimated TV advertising budget of the two.